Back to Resource Library
Integrating Long-acting Injectable Cabotegravir for HIV Prevention into the Brazilian Public Health System (ImPrEP CAB Brasil): A hybrid type-2 implementation-effectiveness cohort study

This article from the Lancet HIV describes the results of the IMPrEP CAB Brasil study, which evaluated the feasibility of integrating same-day injectable cabotegravir delivery within the Brazilian public health system.